Drugs / Alpaloritovorelli antibodies
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06760676 | Dec 2025 → May 2027 expected | cervical cancer, esophageal cancer, non-small cell lung carcinoma | Anhui Provincial Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alpaloritovorelli antibodies | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06760676 ↗ |
| Known as | QL-1706 | “Alpaloritovorelli antibodies (QL-1706) is a new type of combination antibody independently developed by Qilu Pharmaceutical Co., Ltd.” NCT06760676 ↗ |
| Action | Inhibit | “It has the synergistic mechanism of blocking PD-1 and CTLA-4 at the same time.” NCT06760676 ↗ |
| Modality | Monoclonal antibody | “It is composed of IgG4 antibody targeting PD-1 (ipalorimab), and IgG1 antibody targeting CTLA-4 (tuvonralimab) in a fixed proportion.” NCT06760676 ↗ |